Article
Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors.
British journal of cancer - 1 Jan 2018
Ajani Jaffer A, Estrella Jeannelyn S, Chen Qiongrong, Correa Arlene M, Ma Lang, Scott Ailing W, Jin Jiankang, Liu Bin, Xie Min, Sudo Kazuki, Shiozaki Hironori, Badgwell Brian, Weston Brian, Lee Jeffrey H, Bhutani Manoop S, Onodera Hisashi, Suzuki Koyu, Suzuki Akihiro, Ding Sheng, Hofstetter Wayne L, Johnson Randy L, Bresalier Robert S, Song Shumei
Abstract excerpt
BACKGROUND: Overexpression of Galectin-3 (Gal-3), a β-galactoside binding protein, has been noted in many tumour types but its functional significance and clinical utility in gastric adenocarcinoma (GAC) are not well known. METHODS: We studied 184 GAC patients characterised by histologic grade, sub-phenotypes (diffuse vs intestinal), and ethnicity (Asians vs North Americans). Immunohistochemistry was performed to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.